We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can HUM's New Oncology Model Strengthen Its Value-Based Care Strategy?
Read MoreHide Full Article
Key Takeaways
HUM's oncology model spans AON clinics in eight states, easing prior authorization for qualifying practices.
EHR analytics and provider scorecards aim to promote evidence-based cancer treatment decisions.
Humana's Evolent partnership targets better care coordination and more disciplined specialty care spending.
Humana Inc. (HUM - Free Report) is expanding its efforts to improve care delivery and manage treatment costs through a new oncology partnership with Evolent Health and American Oncology Network (AON). The collaboration introduces a cancer care model designed to improve treatment access, encourage evidence-based clinical decisions and reduce administrative hurdles for patients and providers.
The model has been launched across AON clinics in eight states. Under the arrangement, participating oncology practices that demonstrate adherence to established quality and treatment standards can bypass traditional prior authorization requirements for most anticancer drug therapies. This could help patients begin treatment sooner while reducing administrative workloads for physicians. The initiative also incorporates provider education, performance scorecards and automated electronic health record (EHR) reminders to encourage appropriate treatment decisions.
The model also relies on data analytics to support personalized cancer care. The platform, powered by Meaningful Insights Biotech Analytics (MiBA), uses real-time EHR data to generate clinical insights and guide treatment planning. By identifying patterns in clinical information, the technology could help physicians make more informed decisions, promote evidence-based treatment practices and improve care quality.
For Humana, the partnership extends its value-based care approach into complex and expensive specialty treatments. Its more than 20-year relationship with Evolent provides an established foundation for this initiative. The collaboration also broadens Humana's specialty care strategy by bringing payers, oncology providers and technology together. This integrated approach could improve care coordination, promote evidence-based treatment decisions and enhance the overall patient experience while supporting more disciplined healthcare spending.
How Are Competitors Faring?
Some of HUM’s major competitors in the value-based care space are UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) .
Through Optum, UnitedHealth Group also offers oncology care management solutions that combine clinical guidance, evidence-based treatment pathways and provider performance incentives. UNH’s Cancer Guidance Program uses clinical reviews and technology to support appropriate treatment choices, improve care quality and manage specialty treatment expenses.
Through Carelon, Elevance Health operates an Oncology Medical Home model that combines risk-sharing arrangements, evidence-based treatment pathways and personalized patient navigation. ELV’s Cancer Care Engagement program uses predictive analytics to identify patients needing additional support, improving care coordination and helping reduce avoidable hospital admissions.
Humana’s Price Performance, Valuation & Estimates
Shares of HUM have rallied 82.2% over the past year compared with the industry’s rise of 25.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Humana trades at a forward price-to-earnings ratio of 29.08, significantly above the industry average of 15.72. HUM carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Humana’s 2026 earnings is pegged at $9.36 per share, implying a 45.4% drop from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Can HUM's New Oncology Model Strengthen Its Value-Based Care Strategy?
Key Takeaways
Humana Inc. (HUM - Free Report) is expanding its efforts to improve care delivery and manage treatment costs through a new oncology partnership with Evolent Health and American Oncology Network (AON). The collaboration introduces a cancer care model designed to improve treatment access, encourage evidence-based clinical decisions and reduce administrative hurdles for patients and providers.
The model has been launched across AON clinics in eight states. Under the arrangement, participating oncology practices that demonstrate adherence to established quality and treatment standards can bypass traditional prior authorization requirements for most anticancer drug therapies. This could help patients begin treatment sooner while reducing administrative workloads for physicians. The initiative also incorporates provider education, performance scorecards and automated electronic health record (EHR) reminders to encourage appropriate treatment decisions.
The model also relies on data analytics to support personalized cancer care. The platform, powered by Meaningful Insights Biotech Analytics (MiBA), uses real-time EHR data to generate clinical insights and guide treatment planning. By identifying patterns in clinical information, the technology could help physicians make more informed decisions, promote evidence-based treatment practices and improve care quality.
For Humana, the partnership extends its value-based care approach into complex and expensive specialty treatments. Its more than 20-year relationship with Evolent provides an established foundation for this initiative. The collaboration also broadens Humana's specialty care strategy by bringing payers, oncology providers and technology together. This integrated approach could improve care coordination, promote evidence-based treatment decisions and enhance the overall patient experience while supporting more disciplined healthcare spending.
How Are Competitors Faring?
Some of HUM’s major competitors in the value-based care space are UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) .
Through Optum, UnitedHealth Group also offers oncology care management solutions that combine clinical guidance, evidence-based treatment pathways and provider performance incentives. UNH’s Cancer Guidance Program uses clinical reviews and technology to support appropriate treatment choices, improve care quality and manage specialty treatment expenses.
Through Carelon, Elevance Health operates an Oncology Medical Home model that combines risk-sharing arrangements, evidence-based treatment pathways and personalized patient navigation. ELV’s Cancer Care Engagement program uses predictive analytics to identify patients needing additional support, improving care coordination and helping reduce avoidable hospital admissions.
Humana’s Price Performance, Valuation & Estimates
Shares of HUM have rallied 82.2% over the past year compared with the industry’s rise of 25.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Humana trades at a forward price-to-earnings ratio of 29.08, significantly above the industry average of 15.72. HUM carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Humana’s 2026 earnings is pegged at $9.36 per share, implying a 45.4% drop from the year-ago period.
Image Source: Zacks Investment Research
HUM stock currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.